<DOC>
	<DOCNO>NCT01488110</DOCNO>
	<brief_summary>The purpose study evaluate efficacy novel therapy treatment migraine , pain reduction relief associate symptom ongoing migraine attack , presence preventive effect two month post treatment . Another purpose investigate treatment affect manifestation autonomic nervous system activity .</brief_summary>
	<brief_title>Investigation Efficacy Outcome New Medical Device Treatment Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Female male subject , otherwise good health , 20 55 year age Subjects meet ICHD2 ( 2nd Edition The International Headache Classification ) criteria migraine headache Subjects minimum 1 migraine attack per month Attack duration 4 72 hour Normal attack intensity least 4 010 VASscale Completed heart surgery Cardiovascular diseases Vascular damage neck vessel Diseases migraine CNS Severe disease vital body organ Severe psychiatric disorder More 6 migraine attack per month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>